Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.66 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.66 |
| ▸ | FAP | Q12884 | 19/20 | 0.64 |
| ▸ | PREP | P48147 | 7/20 | 0.64 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.59 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3641383 | 1.00 | DPP4 (0.66) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL8286531 | 0.81 | FAP (0.72) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL3204887 | 0.79 | DPP4 (1.00) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL8243717 | 0.78 | FAP (1.00) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL8285595 | 0.78 | FAP (0.72) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL8285586 | 0.78 | DPP4 (1.00) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL29362440 | 0.78 | FAP (1.00) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL7901012 | 0.78 | DPP4 (1.00) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL8244087 | 0.78 | FAP (1.00) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL8244085 | 0.78 | DPP4 (0.66) | DPP4DPP7FAPPREPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011005929-A1 | PIPERIDINE DERIVATIVE AND ITS USE FOR THE TREATMENT OF DIABETS AND OBESITY | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-7786312-B2 | Methods of preparing heterocyclic boronic acids and derivatives thereof | PHENOMIX CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080300413-A1 | Methods of Preparing Hetercyclic Boronic Acids and Derivatives Thereof | SINO-MED INTERNATIONAL ALLIANCE, INC. | 2008-12-04 | — | — | US | disclosed |
| EP-1919485-A1 | METHODS OF PREPARING HETERCYCLIC BORONIC ACIDS AND DERIVATIVES THEREOF | Phenomix Corporation (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007016356-A1 | METHODS OF PREPARING HETERCYCLIC BORONIC ACIDS AND DERIVATIVES THEREOF | PHENOMIX CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300413-A1 | Methods of Preparing Hetercyclic Boronic Acids and Derivatives Thereof | HLCS, NISCH, BTD | DPP4 1428/4885DPP7 1927/4885FAP 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.